Kinoxis Therapeutics is a private, Australian-based, clinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders. Kinoxis’ development candidates are novel, small molecules that were discovered through a comprehensive medicinal chemistry and screening program at the University of Sydney. Kinoxis is backed by Uniseed, Australia’s longest running venture fund, and a consortium of sophisticated investors, and secured funding from the US National Institutes of Health National Institute on Drug Abuse for the development of its lead compound to mitigate opioid withdrawal symptoms. Kinoxis’ lead candidate (KNX100) is being developed for the mitigation of opioid withdrawal symptoms. KNX100 has a novel, undisclosed mechanism of action and has completed a Phase I clinical study. The company is also exploring other indications for KNX100, as promising preclinical results have been achieved in animal models of cocaine, methamphetamine, nicotine, and alcohol use disorders, as well as models of agitation and aggression. Kinoxis’ second series of compounds target the oxytocin receptor, through either selective partial agonism or positive allosteric modulation. The brain oxytocin system has been identified as perhaps the most important molecular target for regulating social behaviour and is therefore a major target of interest for treating a wide range of mental disorders. The development of these compounds will be focused on treating conditions that feature social dysfunction as a core symptom, such as neurodevelopmental disorders (including autism spectrum disorder) social anxiety disorder, dementia (including Alzheimer’s disease), and schizophrenia.
View Top Employees from Kinoxis Therapeutics Pty LtdWebsite | http://www.kinoxistherapeutics.com |
Revenue | $3 million |
Employees | 16 (8 on RocketReach) |
Founded | 2017 |
Phone | +61 439 080 353 |
Technologies |
JavaScript,
HTML,
PHP
+9 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Therapeutics, Health Care |
Competitors | BIONOMICS LIMITED, Invitrocue, National Biologics Facility, Novelty Nobility Inc. |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies |
Looking for a particular Kinoxis Therapeutics Pty Ltd employee's phone or email?
The Kinoxis Therapeutics Pty Ltd annual revenue was $3 million in 2024.
Hugh Alsop is the CEO of Kinoxis Therapeutics Pty Ltd.
8 people are employed at Kinoxis Therapeutics Pty Ltd.
Kinoxis Therapeutics Pty Ltd is based in Melbourne, Victoria.
The NAICS codes for Kinoxis Therapeutics Pty Ltd are [5417, 54171, 541, 54, 541714].
The SIC codes for Kinoxis Therapeutics Pty Ltd are [87, 873].